StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Jefferies Continues to See Low Probablity of Sarepta (SRPT) Approval
June 7, 2016 7:50 AM
price target on Jefferies analyst Gena Wang maintained her Underperform rating and $7 PT on Sarepta Therapeutic (NASDAQ: SRPT), saying ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
FDA
Next Articles
Piper Jaffray Remains Negative on Sarepta (SRPT), 'Unable to Handicap Chances for AA'
June 7, 2016 9:08 AM
Sarepta (SRPT): Accelerated Approval Seen Pending Dystrophin Data Analysis - Oppenheimer
June 7, 2016 6:49 AM
Wedbush Upgrades Sarepta Therapeutic (SRPT) to Outperform, $36 PT
June 7, 2016 6:40 AM
Sarepta (SPRT): FDA Request for Dystrophin Data a 'Clear Indication Willing to Grant Accelerated Approval' - Baird
June 7, 2016 6:25 AM
Amid Dystrophin Data Request, Uncertainty Remains in Sarepta (SRPT) - Leerink
June 7, 2016 6:16 AM
Sarepta Therapeutics (SRPT) Says FDA Requests Dystrophin Data
June 6, 2016 5:41 PM
Sarepta Therapeutics Announces FDA Request For Dystrophin Data Prior To Making A Decision on Eteplirsen NDA
June 6, 2016 5:40 PM
